Sarah Matcha
Nurse Practitioner · Fargo, NDNPI 1891944013
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,294 of the $16,637 with a category attached, or 73.9%. 24 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 52.5% of the total. Reporting peaked in 2021 at $14,860 and has fallen 98.6% since, to $208 in 2025. Among nurse practitioner clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $164.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$9K
- Acorda Therapeutics, Inc$7K
- Amneal Pharmaceuticals LLC$192
- Acadia Pharmaceuticals Inc$158
- Teva Pharmaceuticals USA, Inc.$138
- Abbott$113
- plus $609 from 18 others
What the payments were for
- Consulting fees$2,01312%
- Speaking & faculty fees$12,29474%
- Travel & lodging$8245%
- Food & beverage$1,5069%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 13 | $8,734 |
| Acorda Therapeutics, Inc | 30 | $6,693 |
| Amneal Pharmaceuticals LLC | 8 | $192 |
| Acadia Pharmaceuticals Inc | 8 | $158 |
| Teva Pharmaceuticals USA, Inc. | 8 | $138 |
| Abbott | 6 | $113 |
| TG Therapeutics, Inc. | 3 | $77 |
| Boston Scientific | 2 | $59 |
| Biohaven Pharmaceuticals, Inc. | 1 | $56 |
| Sanofi | 2 | $51 |
| AbbVie | 3 | $49 |
| Eisai Inc. | 2 | $47 |
| Lilly USA, LLC | 2 | $36 |
| Biogen | 2 | $29 |
| Adamas Pharmaceuticals, Inc. | 2 | $29 |
| GE HealthCare | 1 | $28 |
| Microtransponder, Inc. | 1 | $26 |
| Mirum Pharmaceuticals, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,637 in reported general payments places this provider in the 95th percentile of 455 nurse practitioner providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 40 | $299,718 |
| NuplazidPimavanserin Tartrate | 52 | $252,952 |
| RytaryCarbidopa/Levodopa | 206 | $245,841 |
| AustedoDeutetrabenazine | 24 | $222,564 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,055 | $59,083 |
| Rasagiline Mesylate | 159 | $34,769 |
| MyrbetriqMirabegron | 46 | $24,090 |
| NourianzIstradefylline | 12 | $21,000 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 275 | $16,629 |
| Rivastigmine | 75 | $11,504 |
| Carbidopa | 25 | $7,771 |
| Dalfampridine ErDalfampridine | 15 | $7,321 |
| Donepezil Hcl | 362 | $6,133 |
| Gabapentin | 272 | $5,842 |
| Primidone | 129 | $5,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $8,734 | $299,71840 claims |
| Acadia Pharmaceuticals IncNuplazid | $158 | $252,95252 claims |
| Amneal Pharmaceuticals LLCRytary | $192 | $245,841206 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $138 | $222,56424 claims |
| Kyowa Kirin, Inc.Nourianz | $16 | $21,00012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 nurse practitioner providers in North Dakota.
Other nurse practitioner in Fargo
- Emily GreensteinFargo$271K
- Jana SuderFargo$16K
- Andrea HansonFargo$5K
- Leah WoldenFargo$3K
- Richard SchueFargo$2K
- Tyroniesha ReedFargo$2K
- Roberta StigenFargo$2K
- Haley FisherFargo$2K
- Jessie PeckaFargo$2K
- Brooke CampbellFargo$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.